loading
Agios Pharmaceuticals Inc stock is traded at $38.80, with a volume of 722.57K. It is up +1.57% in the last 24 hours and down -2.17% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$38.20
Open:
$38.25
24h Volume:
722.57K
Relative Volume:
1.00
Market Cap:
$2.25B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.4155
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+4.84%
1M Performance:
-2.17%
6M Performance:
+10.16%
1Y Performance:
-15.10%
1-Day Range:
Value
$37.75
$39.69
1-Week Range:
Value
$35.92
$39.69
52-Week Range:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Name
Agios Pharmaceuticals Inc
Name
Phone
617-649-8600
Name
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
488
Name
Twitter
@AgiosPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
38.80 2.18B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Initiated H.C. Wainwright Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-10-24 Resumed Raymond James Outperform
Sep-27-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-08-24 Initiated Cantor Fitzgerald Overweight
Feb-03-23 Initiated Piper Sandler Overweight
Nov-17-22 Upgrade Goldman Sell → Neutral
Jul-27-22 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-03-21 Initiated BofA Securities Buy
Jul-30-21 Downgrade Goldman Neutral → Sell
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-10-21 Initiated H.C. Wainwright Buy
Mar-01-21 Downgrade JP Morgan Overweight → Neutral
Mar-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Feb-26-21 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20 Upgrade Barclays Equal Weight → Overweight
Mar-04-20 Initiated Barclays Equal Weight
Nov-26-19 Initiated Cantor Fitzgerald Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
May-23-19 Resumed Goldman Neutral
Feb-15-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-25-18 Initiated Leerink Partners Mkt Perform
May-23-18 Initiated Citigroup Buy
Apr-11-18 Reiterated Credit Suisse Outperform
Feb-15-18 Reiterated Needham Buy
Feb-15-18 Reiterated SunTrust Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Aug-10-17 Reiterated Needham Buy
Aug-08-17 Reiterated SunTrust Buy
Aug-02-17 Upgrade Leerink Partners Mkt Perform → Outperform
Jun-26-17 Downgrade Janney Buy → Neutral
Jan-17-17 Upgrade Oppenheimer Perform → Outperform
Oct-24-16 Initiated Needham Buy
Jun-13-16 Upgrade JP Morgan Neutral → Overweight
May-18-16 Reiterated SunTrust Buy
View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

pulisher
Aug 16, 2025

Can Agios Pharmaceuticals Inc. withstand a market correction2025 Sector Review & Consistent Growth Equity Picks - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 15, 2025

How to track smart money flows in Agios Pharmaceuticals Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Performance Recap & Long-Term Safe Return Strategies - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyJuly 2025 Movers & AI Optimized Trade Strategies - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Can Agios Pharmaceuticals Inc. generate free cash flowCEO Change & Weekly Sector Rotation Insights - thegnnews.com

Aug 14, 2025
pulisher
Aug 13, 2025

Published on: 2025-08-13 06:00:50 - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

How institutional ownership impacts Agios Pharmaceuticals Inc. stockJuly 2025 Action & Weekly High Potential Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈

Aug 12, 2025
pulisher
Aug 12, 2025

Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire

Aug 12, 2025
pulisher
Aug 11, 2025

Full technical analysis of Agios Pharmaceuticals Inc. stockLow Exposure Strategy with Sector Analysis - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

How Agios Pharmaceuticals Inc. stock performs during market volatilityMachine Learning Stock Price Forecast Tool - Newser

Aug 11, 2025
pulisher
Aug 09, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance

Aug 08, 2025
pulisher
Aug 07, 2025

Agios Pharmaceuticals Shares Plunge 23% Amid Safety Concerns - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

TR | OpenAI4o Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $38 - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

Can a trend reversal in Agios Pharmaceuticals Inc. lead to recoveryChart Driven Entry Timing for Swing Trades - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Agios Shares Fall 15% After Report of Deaths Among Pyrukynd Patients - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com

Aug 05, 2025
pulisher
Aug 05, 2025

Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech

Aug 05, 2025
pulisher
Aug 05, 2025

Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace

Aug 05, 2025
pulisher
Aug 05, 2025

Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

Envestnet Asset Management Inc. Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns - Asianet Newsable

Aug 05, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria

Aug 04, 2025
pulisher
Aug 04, 2025

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times

Aug 04, 2025
pulisher
Aug 04, 2025

Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 04, 2025
pulisher
Aug 04, 2025

Agios evaluating fourth Pyrukynd case after analyst report - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals Becomes Oversold (AGIO) - Nasdaq

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 03, 2025

How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Aug 02, 2025
pulisher
Aug 01, 2025

Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN

Aug 01, 2025

Agios Pharmaceuticals Inc Stock (AGIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Smith Cynthia
Director
Aug 11 '25
Option Exercise
0.00
2,302
0
12,414
Goff Brian
Chief Executive Officer
Aug 08 '25
Option Exercise
0.00
22,691
0
134,613
Goff Brian
Chief Executive Officer
Aug 08 '25
Sale
36.67
11,085
406,487
123,528
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):